Geron raised a ton of money through dilutive stock sales in the second quarter — a signal that management has low confidence for extending the lifespan of its partnership with Janssen, the pharma arm of Johnson & Johnson.

Before the current quarter ends, Janssen will decide if it wants to commit millions of dollars more to co-develop the experimental blood disease drug imetelstat with Geron. Or, the pharma giant will choose to walk away, returning rights to the drug to Geron.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • It’s simple… AF must bash the stock down so he and his big$ bankers can cover before price breakout… leaving majority if not all of his followers with empty pockets! I suppose this is what you get for following an individual that is in it for manipulating prices. GLTA AF followers!~

  • Maybe Adam needs to refresh his memory on his own comment regarding the rule he and his partner Dr. Ratain made – reference this 2013 article from Motley Fool to see what Adam said back then. Adam’s quote from that article sure sounds a lot like JNJ and Geron…and Geron’s market cap may not be a billion but it’s more than 300M.

    And if the “fund raising” activity is the primary focus of this article and in fact reason for Geron’s eventual demise, then (1) why were they listed on the updated pipeline after that fund raising activity took place (2) why is Janssen actively applying for patents after the fund raising activity (3) and why is Janssen all set to actively recruit for the next phase? Seems like not only is Adam ignoring his own rule but he’s also ignoring several other positive markers that all occurred and have updates after the fund raising activity he’s referring to.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy